<DOC>
	<DOCNO>NCT00985777</DOCNO>
	<brief_summary>The purpose study determine safest dose study drug Vitamin E Delta-tocotrienol , often take , well people pancreatic tumor tolerate Vitamin E Delta-tocotrienol .</brief_summary>
	<brief_title>Vitamin E δ-Tocotrienol Administered Subjects With Resectable Pancreatic Exocrine Neoplasia</brief_title>
	<detailed_description>Delta-tocotrienol natural Vitamin E compound consume human dietary supplement . The Food Drug Administration ( FDA ) approve sale drug . Vitamin E Delta-tocotrienol investigated prevention treatment pancreatic tumor . The usefulness Vitamin E Delta-tocotrienol treat human tumor unknown . This study consist follow : ( 1 ) Pre-Treatment Period participant consent qualified study ; ( 2 ) Study Treatment Period participant receive Vitamin E δ-Tocotrienol administer orally twice daily 14 ( ±2 ) consecutive day day surgery , associate pharmacokinetic pharmacodynamic sampling ; ( 3 ) Post Treatment Period laboratory physical examination perform . Adverse event record throughout study .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin E</mesh_term>
	<mesh_term>Tocopherols</mesh_term>
	<mesh_term>Tocotrienols</mesh_term>
	<mesh_term>alpha-Tocopherol</mesh_term>
	<criteria>The patient resectable tumor cyst arise pancreatic exocrine gland ( pancreatic ductal adenocarcinoma , intraductal papillary mucinous neoplasm pancreas , mucinous cystic neoplasm pancreas ) undergo surgical resection neoplasm . The patient candidate neoadjuvant chemoradiation therapy ( i.e. , patient borderline resectable pancreatic ductal adenocarcinoma know benefit neoadjuvant treatment regimen ) . The patient Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 . The patient adequate organ function follow : Serum creatinine ≤1.5 mg/dL calculate creatinine clearance &gt; 60 mL/min ; Bilirubin ≤ institutional upper limit normal ( ULN ) ; Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤2.5 time upper limit normal liver involvement ≤5 time upper limit normal liver involvement ; absolute neutrophil count ( ANC ) ≥ 1000mm³ ; Platelet count ≥100,000/mm³ . The patient capability understanding informed consent document sign informed consent document . Sexually active patient ( male female ) must use medically acceptable method contraception course study . Female patient childbearing potential must negative pregnancy test screening . Able understand comply requirement protocol . The patient receive concomitant radiotherapy , chemotherapy , antineoplastic therapy , investigational therapy ( investigational therapy study ) . The patient receive radiation therapy , chemotherapy , antineoplastic therapy , investigational therapy within 30 day prior first dose study drug . The patient prior major surgery within 30 day prior first dose study drug . The patient active infection fever &gt; 38.5 C within 3 day prior first dose study drug . The patient uncontrolled intercurrent illness include , limited , ongoing active infection , hypertension , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . The patient unable unwilling stop taking vitamin , herbal remedy , nonprescription medication . The patient pregnant breastfeeding . The patient unable unwilling abide study protocol cooperate fully investigator designee . The patient candidate neoadjuvant radiation therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>pancreas</keyword>
	<keyword>resectable</keyword>
	<keyword>pancreatic tumor</keyword>
	<keyword>pancreatic ductal adenocarcinoma</keyword>
	<keyword>intraductal papillary mucinous neoplasm pancreas</keyword>
	<keyword>mucinous cystic neoplasm</keyword>
	<keyword>pancreatic exocrine neoplasia</keyword>
</DOC>